Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Indianapolis, Indiana


Purpose:

This study is to test whether or not 32mg of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.


Criteria:

Inclusion Criteria: - Type 1 or Type 2 diabetes mellitus - 18 years or older - Meet specific requirements for diabetic retinopathy - Free of severe or chronically disabling conditions, except diabetes, diabetic retinopathy and diabetic macular edema - HbA1C <= 13.0% Exclusion Criteria: - History of panretinal photocoagulation for diabetic retinopathy, conditions that might affect the progression of diabetic retinopathy, or unstable angina - Investigators, site personnel directly affiliated with the study and their families - Presence of eye disorders that may affect the progression of diabetic retinopathy or cause vision loss - Presence of medical disorder, cancer, or elevated measurements that could pose a safety risk during the study - Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually active without using an acceptable method of birth control


NCT ID:

NCT00604383


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Indianapolis, Indiana
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.